Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 9:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28,884 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral Clear all
Terminated Phase 3 Interventional

Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

NCT00009906
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
Imatinib Mesylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
132
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 99 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Sep 12, 2026, 9:29 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment

NCT03097016
View directory record Official record
Conditions
Renal Insufficiency
Interventions
CC-122
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Lakewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 12, 2026, 9:29 PM EDT
Completed Phase 2 Interventional Results available

A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease

NCT00724048
View directory record Official record
Conditions
Huntington Disease
Interventions
ACR16, Placebo
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
22
States / cities
Birmingham, Alabama • San Diego, California • Littleton, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 12, 2026, 9:29 PM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction After Switching to Oral Testosterone Undecanoate

NCT04983940
View directory record Official record
Conditions
Testosterone Deficiency
Interventions
Jatenzo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 12, 2026, 9:29 PM EDT
Terminated Phase 1Phase 2 Interventional

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

NCT05123040
View directory record Official record
Conditions
Acute-graft-versus-host Disease
Interventions
Ruxolitinib 10 MG Oral Tablet, hCG, Corticosteroids
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 12, 2026, 9:29 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940
View directory record Official record
Conditions
HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 12, 2026, 9:29 PM EDT
Completed Phase 2 Interventional Results available

Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer

NCT02549989
View directory record Official record
Conditions
Endometrial Cancer, Recurrent Endometrial Cancer
Interventions
LY3023414
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 12, 2026, 9:29 PM EDT
Completed Phase 1 Interventional

Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors

NCT00345189
View directory record Official record
Conditions
Tumors, Lymphoma
Interventions
CNF2024
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Scottsdale, Arizona • New Haven, Connecticut • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2009 · Synced Sep 12, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants

NCT02540668
View directory record Official record
Conditions
Healthy
Interventions
Lanabecestat, Warfarin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Sep 12, 2026, 9:29 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Neuroprotection in Acute Ischemic Stroke

NCT03320018
View directory record Official record
Conditions
Stroke, Ischemic
Interventions
Hydrogen, Minocycline, Placebo Hydrogen, Placebo Minocycline
Drug · Other
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 12, 2026, 9:29 PM EDT
Completed Phase 1 Interventional

Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion

NCT01997190
View directory record Official record
Conditions
Malignant Pleural Effusion, Lung Cancer, Mesothelioma, Breast Cancer, Ovarian Cancer
Interventions
AdV-tk + valacyclovir
Biological
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 12, 2026, 9:29 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Hyperandrogenemia and Altered Day-night LH Pulse Patterns

NCT03068910
View directory record Official record
Conditions
Hyperandrogenism, Polycystic Ovary Syndrome, Puberty
Interventions
Micronized progesterone, Spironolactone, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 17 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 12, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants

NCT06111521
View directory record Official record
Conditions
Healthy
Interventions
LY3537982, Digoxin, Rosuvastatin, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Sep 12, 2026, 9:29 PM EDT
Completed Phase 3 Interventional Results available

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

NCT01395914
View directory record Official record
Conditions
Cachexia, Non-Small Cell Lung Cancer
Interventions
Anamorelin HCl, Placebo
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
19
States / cities
Corona, California • Fountain Valley, California • Fullerton, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 12, 2026, 9:29 PM EDT
Not yet recruiting Not applicable Interventional

Prevention of Oral Mucositis in Adults in With Hematologic Malignancy

NCT07809984
View directory record Official record
Conditions
Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Oral Mucositis
Interventions
Aloe Vera Mouthwash, Standard of Care
Dietary Supplement · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Oak Lawn, Illinois • Park Ridge, Illinois • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 12, 2026, 9:29 PM EDT
Terminated Phase 2 Interventional Results available

A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee

NCT01147458
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
PF-04191834, PF-04191834 placebo, Naproxen placebo, Naproxen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Peoria, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Sep 12, 2026, 9:29 PM EDT
Completed Phase 2 Interventional Results available

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

NCT03030248
View directory record Official record
Conditions
Clostridium Difficile Infection, Hematologic Diseases, Bone Marrow Transplant, Oncologic Disorders
Interventions
Vancomycin Oral Capsule, Placebo Oral Capsule
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 12, 2026, 9:29 PM EDT
Completed Phase 1 Interventional

A Study of ASN007 in Patients With Advanced Solid Tumors

NCT03415126
View directory record Official record
Conditions
Cancer, Malignancy, Neoplasia, Neoplasm, Neoplasm Metastasis, Colon Cancer, Colonic Neoplasms, Colon Cancer Liver Metastasis, Metastatic Cancer, Metastatic Melanoma, Metastatic Colon Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer Metastatic, Pancreatic Cancer, Pancreas Cancer, Pancreas Adenocarcinoma, Pancreas Neoplasm, Metastatic Nonsmall Cell Lung Cancer, Metastatic Pancreatic Cancer
Interventions
ASN007: ascending doses, ASN007 RD
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Tampa, Florida • Boston, Massachusetts • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 12, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

NCT01372826
View directory record Official record
Conditions
Renal Impairment
Interventions
NKTR118 Group1, NKTR118 Group 2, NKTR118 Group3, NKTR118
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
3
States / cities
Anaheim, California • Orlando, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 12, 2026, 9:29 PM EDT
Active, not recruiting Phase 1 Interventional

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

NCT06496568
View directory record Official record
Conditions
PIK3CA-Mutated Cancers
Interventions
Inavolisib, Atezolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 12, 2026, 9:29 PM EDT
Completed Not applicable Interventional

Whipple Protein Study

NCT04306874
View directory record Official record
Conditions
Pancreatic Cancer, Malnutrition
Interventions
Ensure Max Protein
Dietary Supplement
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Sep 12, 2026, 9:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer

NCT00828074
View directory record Official record
Conditions
Breast Cancer
Interventions
sorafenib tosylate, vinorelbine ditartrate
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 12, 2026, 9:29 PM EDT
Terminated Phase 2 Interventional

A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease

NCT00890890
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Avagacestat, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
45 Years to 90 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
50
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 12, 2026, 9:29 PM EDT
Not listed Phase 1 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer

NCT00004097
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
fluorouracil, gemcitabine hydrochloride, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 12, 2026, 9:29 PM EDT